Top Markets
Coin of the day
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Hisse Senetlerindeki Sıralama #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Hisse Fiyatı
$0.15
Piyasa Değeri
$4.96M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
CA
Ticaret Intellipharmaceutics International Inc. (IPCIF)

Kategori

Intellipharmaceutics International Inc. (IPCIF) için gelir
Aug 2023 itibarıyla gelir TTM: $904.95K
Intellipharmaceutics International Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $904.95K'dir. 2021 yılında şirketin geliri $65.73K önceki yıla göre azalma 2020 yılındaki $1.40M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Intellipharmaceutics International Inc. için 1999 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2026 (TTM) $904.95K 1,276.80%
2022 $65.73K 0.00%
2021 $65.73K -95.31%
2020 $1.40M 0.00%
2019 $1.40M -18.17%
2018 $1.71M -68.88%
2017 $5.50M 144.97%
2016 $2.25M -45.11%
2015 $4.09M -53.32%
2014 $8.77M 474.13%
2013 $1.53M 1,326.33%
2012 $107.09K -78.66%
2011 $501.81K -65.61%
2010 $1.46M 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 $1.00K 0.02%
2000 $999.82 -99.00%
1999 $100.06K 0.00%
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$48.44B 5,352,315.73%
DK
$12.04B 1,330,189.32%
US
$14.34B 1,584,845.40%
US
$9.08B 1,003,525.57%
BE
$5.49B 606,708.00%
NL